Carboplatin

“including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗

“Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Carboplatin; * Irinotecan; * Etoposide; *...” NCT03632135 ↗

“Camrelizumab 200 mg (Day 1) intravenous infusion (IV) and Paclitaxel Albumin - bound 125 mg/m² (Day 1, Day 8) IV and Carboplatin AUC 4 (Day 1) IV, with a 21-day cycle for 2...” NCT07432087 ↗

“One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗

“We performed a prospective, randomized, phase III, intergroup trial to compare carboplatin plus paclitaxel (TC; area under the curve [AUC] 5 and 175 mg/m(2), respectively) with...” PMID 20733132 ↗ Aug 2010

“Patients received neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2, day 1 and 8 of each 21-day cycle, intravenous), trastuzumab (6 mg/kg on day 1 of each cycle...” PMID 41713473 ↗ Feb 2026

“After the start of External Beam Radiation Therapy (EBRT), paclitaxel (150-175 mg/m2) or paclitaxel (albumin-bound) 222-260 mg/m2 + cisplatin (60-75 mg/m2) or carboplatin...” NCT06870565 ↗

“Fluorouracil, 1000 mg/m2 per day, intravenously for days 1 to 4; cisplatin, 70 mg/m2 (or carboplatin, area under the curve, 5) intravenously on day 1; and pembrolizumab, 200...” PMID 40965911 ↗ Nov 2025

“Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours...” NCT02856997 ↗

“Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed...” NCT04951648 ↗

“Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by...” NCT07608159 ↗

“Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous),...” NCT06865339 ↗

“Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam...” NCT05255653 ↗

“platinum-based doublet chemotherapy (carboplatin [area under the curve ≤700 mg] plus pemetrexed [500 mg/m2 intravenous infusion every 3 weeks] or carboplatin [on day 1; area...” PMID 39486424 ↗ Oct 2024

“Patients were randomly assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2, and platinum [cisplatin, 75 mg/m2; carboplatin, area...” PMID 37535377 ↗ Oct 2023

“Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗

“The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗

“Safety & Efficacy of Neoadjuvant Immunotherapy With Durvalumab (MEDI 4736) Combined With Neoadjuvant Chemotherapy (Gemcitabine/Cisplatin or Gemcitabine/Carboplatin) in Patients...” NCT04617756 ↗

“Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV...” NCT04581824 ↗

“Chemotherapy was either cisplatin (70 mg/m2) or carboplatin (area under the curve [AUC]4·5/AUC5, for glomerular filtration rate <50 mL/min only) administered intravenously on...” PMID 32145825 ↗ Mar 2020

“The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by...” PMID 39671272 ↗ Feb 2025

“IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR...” NCT06253871 ↗

“Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant...” NCT02249013 ↗

“Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in...” NCT06072612 ↗

“mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles -...” NCT03110926 ↗

“Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W)...” NCT06276933 ↗

“Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1...” NCT07121374 ↗

“Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning...” PMID 39134959 ↗ Aug 2024

“Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Liposomal Doxorubicin; * Docetaxel; *...” NCT03949283 ↗

“Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing)...” NCT04028050 ↗

“Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC;...” NCT05940532 ↗

“with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel...” NCT05962021 ↗

“AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel...” NCT05378334 ↗

“After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab...” NCT06304350 ↗

“Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous...” NCT06930794 ↗

“They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel,...” NCT04282356 ↗

“Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at...” NCT00739830 ↗

“The study is aimed to evaluate the efficacy of investigator's choice (ICC) of chemotherapy (nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone)...” NCT05954442 ↗

“The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third...” NCT03077243 ↗

“platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different...” NCT02891824 ↗

“Two hundred twenty-nine chemotherapy-naive patients with advanced-stage NSCLC were enrolled onto a phase II selection trial evaluating sequential or concurrent chemotherapy...” PMID 18612151 ↗ Jul 2008

“Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel,...” NCT05383001 ↗

“non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed...” NCT06769295 ↗

“Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was...” NCT00312728 ↗

“Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135...” NCT06731413 ↗

“Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed...” NCT03921671 ↗

“Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3...” NCT06667154 ↗

“Non-squamous NSCLC subjects will receive pemetrexed/albumin paclitaxel and platinum (cisplatin/carboplatin), and squamous NSCLC subjects will receive albumin paclitaxel and...” NCT06485557 ↗

“Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan...” PMID 22622008 ↗ May 2012

“Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the...” NCT04677816 ↗

“They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks...” PMID 29432076 ↗ Feb 2018

“Carboplatin is administered intra-arterially during BACE in cycles with the procedure; if BACE is not performed in a given cycle, carboplatin is administered intravenously on...” NCT07561983 ↗

“Platinum-based agent: either Cisplatin 75 mg/m² on Day 1, intravenous infusion, Q3W, or Carboplatin AUC = 5 on Day 1, intravenous infusion, Q3W; the specific agent is at the...” NCT07514793 ↗

“Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus...” NCT00318370 ↗

“According to the NCCN Guidelines (2024.V2), the first-line chemotherapy regimen for persistent, recurrent, or metastatic cervical cancer is preferably carboplatin/paclitaxel...” NCT07153952 ↗

“Dosing of chemotherapy is etoposide 90mg/m² body surface area (BSA) day 1-3 in combination with cisplatin 75mg/m² BSA on day 1 or carboplatin area under the curve (AUC) 5 mg/ml...” NCT06223711 ↗

“For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and...” NCT05691829 ↗

“Chemotherapy (cisplatin 40 mg/m2 intravenously or carboplatin AUC 2 intravenously) will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15,...” NCT04620187 ↗

“Participants will undergo tumor harvest for TIL and then receive 2 to 3 cycles of pembrolizumab or pembrolizumab/platinum chemotherapy (cisplatin or carboplatin / 5-FU) as per...” NCT06236425 ↗

“Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin:...” NCT05880082 ↗

“if cisplatin-related non-hematological toxicity occurs, treatment may switch to carboplatin area under the curve(AUC)=5; if cisplatin intolerant patients, carboplatin(AUC=5)...” NCT07509099 ↗

“Enrolled eligible subjects will be started on systemic chemotherapy (pemetrexed and carboplatin or cisplatin) within 6 weeks of starting osimertinib, with the following outcome...” NCT06918782 ↗

“Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗

“Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration time curve of 5 \[AUC5\] by using the Calvert formula)” NCT05338970 ↗

“Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist.” NCT04905316 ↗

“The treatment regimen includes the administration of Camrelizumab at a dose of 200 mg, Paclitaxel (albumin-bound) at 260 mg/m², and Carboplatin with an area under the curve (AUC) of 5.” NCT07505186 ↗

“Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.” NCT05684731 ↗

“Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.” NCT05050630 ↗

“R-ICE:rituximab 375mg/m\^2 before chemotherapy, ifosfamide 5g/m\^2 24 hours continuous infusion (CI) on Day 2+mesna, carboplatin area under the curve (AUC)5 Day 2, maximum dose 800mg” NCT03391466 ↗

“One of either Cisplatin or Carboplatin. Both agents are potent platinum-based antineoplastic/alkylating agents administered as an IV infusion according to local practice and labels.” NCT05443126 ↗

“Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion.” NCT04364048 ↗

“Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) will be administered via intravenous infusion on Day 1 of each cycle” NCT06485544 ↗

“In cases of significant neuroendocrine differentiation and if well-tolerated, a combination of docetaxel and carboplatin (docetaxel 75 mg/m² and carboplatin AUC 4-6) will be used.” NCT06864533 ↗

“nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w.” NCT01625429 ↗

“six 3-weekly cycles of intravenous paclitaxel [175 mg/m2] or docetaxel [75 mg/m2] combined with intravenous carboplatin [area under the curve of 5 mg/mL per min]; surgery group)” PMID 33705695 ↗ Mar 2021

“Induction Therapy: Two cycles of induction chemotherapy (nab-paclitaxel 200 mg/m², day 1; carboplatin AUC 5, day 1) combined with a PD-1 inhibitor (200 mg, day 1) every 3 weeks.” NCT05621707 ↗

“Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗

“Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.” NCT06218004 ↗

“Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.” NCT03180177 ↗

“Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin.” NCT06718309 ↗

“Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗

“Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.” NCT03373058 ↗

“Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle” NCT03992885 ↗

“adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)” NCT05286957 ↗

“Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.” NCT03818282 ↗

“Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)” NCT03696186 ↗

“Carboplatin AUC 5 or 6 and paclitaxel will be administered at a dose of 175 mg/m2 Q3W, or carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W followed by chemoradiotherapy.” NCT07022483 ↗

“Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously” NCT06671379 ↗

“Carboplatin AUC 5 (or AUC 6 if dose level 3 has been completed) will be administered as a 30 minutes intravenous infusion diluted in 250 mL of normal saline every 3 weeks.” NCT02439489 ↗

“PCT regimens will include both carboplatin or cisplatin plus pemetrexed (for non-squamous histology) or paclitaxel (for squamous histology) in combination with cemiplimab.” NCT07274384 ↗

“Receive neoadjuvant treatment with Ensartinib (taken orally once daily) plus Pemetrexed and Carboplatin (administered intravenously every 3 weeks) for 9 weeks (3 cycles).” NCT07354061 ↗

“Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin).” NCT03248570 ↗

“carboplatin at an AUC of 5, with the total dose (mg) calculated as AUC × (GFR + 25), where GFR refers to glomerular filtration rate, administered via intravenous infusion” NCT07271602 ↗

“Vincristine, etoposide, carboplatin, and cyclophosphamide have been used in many protocols for brain tumors but the result was very poor in refractory or relapsed cases.” NCT01535183 ↗

“Preoperative therapy will either be FLOT for 8 weeks OR concurrent radiation and chemotherapy (carboplatin and paclitaxel or FOLFOX) for 5-6 weeks, per standard of care.” NCT06044311 ↗

“The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle.” NCT01134497 ↗

“Carboplatin + choice of non-platinum chemotherapy drug: taxane, paclitaxel, nab-paclitaxel, gemcitabine or doxorubicin pegylated liposomal with or without bevacizumab.” NCT02759588 ↗

“Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.” NCT06607926 ↗

“Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.” NCT04585477 ↗

“Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC=2) for five weeks, given on the days of radiotherapy.” NCT06509568 ↗

“Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles” NCT04747054 ↗

“carboplatin (area under the concentration-time curve [AUC] 6 mg/mL per min on day 1 or optionally, as per hospital preference, AUC 3 mg/mL per min on days 1 and 8)” PMID 30413379 ↗ Nov 2018

“Subjects who met the conditions of the study population were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2.” NCT05812534 ↗

“Administered intravenously: carboplatin (AUC=5), nab-paclitaxel (260 mg/m²) + 200 mg Sintilimab + Bevacizumab (7.5 mg/kg), every 3 weeks for a total of 12 weeks.” NCT07351487 ↗

“afatinib 40mg qd; carboplatin (AUC 5) on day 1, and pemetrexed (500 mg/m2 for non-squamous carcinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma) d1 q3w” NCT06709859 ↗

“Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).” NCT03663166 ↗

“Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles” NCT04602533 ↗

“PD-1 inhibitor combined with chemotherapy (Paclitaxel or Albumin-bound paclitaxel plus Cisplatin or Carboplatin), administered once every 3 weeks for 2 cycles.” NCT07519486 ↗

“Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.” NCT05524389 ↗

“Patients will recieve 3 cycles of carboplatin and gemcitabine followed by 3 cycles of taxol and carboplatin and then three cycles of adriamycin and topotecan.” NCT00157560 ↗

“BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer” NCT01314105 ↗

“Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles.” NCT05782426 ↗

“Ivonescimab(20mg/kg) combined with paclitaxel polymeric micelles (≤300mg/㎡) and platinum(cisplatin 75mg/㎡or carboplatin AUC5) IV every 3 weeks for 4 cycles.” NCT07009925 ↗

“paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.” NCT06775275 ↗

“Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes” NCT03664115 ↗

“Each cycle of NICE consists of four doses of hu3F8, five doses of GM-CSF, one dose of carboplatin, and 3 doses each of ifosfamide and etoposide (table 2).” NCT06438614 ↗

“INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)” NCT06477692 ↗

“Carboplatin:5/AUC, maximum dose limited to 600mg, or 75 mg/m2 cisplatin, is administered intravenously every three weeks on the first day of each cycle” NCT05448781 ↗

“Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.” NCT04486833 ↗

“Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.” NCT05949021 ↗

“Combined with radiation, patients will receive 2 treatments of IA carboplatin, 400 mg/m2, 4 hours prior to the first and the sixth radiation fraction.” NCT03672721 ↗

“Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines.” NCT04091867 ↗

“first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）” NCT02772107 ↗

“If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.” NCT03514849 ↗

“platinum-based chemotherapy (carboplatin \[area under the curve (AUC) 5 mg/mL per min, IV\] and etoposide \[100 mg/m2, IV, D1-D3\] for ES-SCLC)” NCT06620796 ↗

“Patients receive standard induction chemoimmunotherapy (carboplatin, paclitaxel, and pembrolizumab) in three 21-day cycles, beginning on Day 1.” NCT07335380 ↗

“Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations” NCT04399876 ↗

“Paclitaxel plus Carboplatin (TC) therapy; Paclitaxel (PTX) 175 mg/m2 + Carboplatin(CBDCA) area under curve(AUC) 6 q3weeks day1, 3 to 6 cycles” NCT04063527 ↗

“Platinum-based chemotherapy (carboplatin AUC=5 + pemetrexed 500 mg/m² [adenocarcinoma] or nab-paclitaxel 260 mg/m² [squamous/other subtypes])” NCT06977074 ↗

“Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)” NCT05594290 ↗

“Carboplatin Dose: administered according to the area under the curve (AUC) of 5 mg/mL/min, with infusion time controlled within 15-60 minutes” NCT07177105 ↗

“Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy” NCT01593293 ↗

“Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation” NCT04334759 ↗

“Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label” NCT05256745 ↗

“Iparomlimab/Tuvonralimab 5mg/kg,D1,Q3W + albumin paclitaxel 90mg/m2, D1、8、15，Q3W+ Cisplatin 25mg/m2 or Carboplatin AUC = 1.5 , D1、8、15，Q3W” NCT07613567 ↗

“or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles” NCT04952597 ↗

“Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)” NCT02052960 ↗

“TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen” NCT03387553 ↗

“paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w” NCT04471480 ↗

“Carboplatin: AUC=2 (calculated using the Calvert formula), administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles” NCT07105592 ↗

“Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period” NCT05183984 ↗

“The recommended chemotherapy is based on the current reference combination of platinum (cisplatin or carboplatin) and etoposide (VP16).” NCT04268121 ↗

“Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)” NCT04865250 ↗

“Group A： Albumin-bound paclitaxe (260 mg/m²,d 1)+Carboplatin (AUC=5, d 1)+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;” NCT06817525 ↗

“A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)” NCT01648517 ↗

“Possible platinum doublet chemotherapy regimens are Cisplatin/Carboplatin in combination with Pemetrexed or Docetaxel or Gemcitabine.” NCT06902272 ↗

“Carboplatin with an area under the curve (AUC) of 5 mg/ml/min, intravenous infusion on day 1, every 3 weeks (Q3W), total of 3 cycles” NCT07385001 ↗

“pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve AUC 5 or pemetrexed 500 mg/m2 + cisplatin 75 mg/m2” NCT02151981 ↗

“and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (\*) minute (min) on Day 1 of Cycles 1 through 4 or 6” NCT00531960 ↗

“The starting dose is carboplatin AUC 5mg/ml\*min, cyclophosphamide 600mg/m2 and atezolizumab 840 mg, all administered intravenously.” NCT02914470 ↗

“If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)” NCT04188847 ↗

“Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator.” NCT03977467 ↗

“-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .” NCT03577743 ↗

“Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).” NCT06151743 ↗

“carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or paclitaxel liposome 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks” NCT04084158 ↗

“myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) 9 x retinoic acid cycles” NCT03042429 ↗

“Cisplatin or Carboplatin: Cisplatin 75 mg/m² IV on Day 1 or Cisplatin 25 mg/m² IV on Days 1-3, Or Carboplatin AUC = 5 IV on Day 1” NCT07091305 ↗

“Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3 week treatment cycle” NCT07376499 ↗

“Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle” NCT06951841 ↗

“carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;” NCT06420908 ↗

“Eligible patients will be treated with platinum-based chemotherapy (i.e. cisplatin + gemcitabine or carboplatin + gemcitabine).” NCT06820255 ↗

“Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.” NCT03472053 ↗

“Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles” NCT05295212 ↗

“carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles” NCT00403403 ↗

“albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)” NCT05316376 ↗

“pemetrexed 500 mg/m2 plus platinum [carboplatin, area under curve (AUC) of 5, or cis-platinum 75 mg/m2] for non-squamous NSCLC” PMID 39756446 ↗ Jan 2025

“chemotherapy protocol consisted of albumin-bound paclitaxel (260mg/m2, with a maximum dose of 400mg) + carboplatin (AUC = 5).” NCT07385664 ↗

“Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care” NCT03088059 ↗

“received intravenous paclitaxel (135 mg/m²) and carboplatin (AUC=2-5) on day 1, administered every three weeks for two cycles” NCT06775652 ↗

“All patients will receive three cycles of paclitaxel and carboplatin chemotherapy combined with PD-1/PD-L1 inhibitor therapy” NCT07003620 ↗

“Non-squamous NSCLC: pemetrexed 500 mg/m² IV over 30 min and carboplatin AUC 5 IV over 120 min or per institutional standard.” NCT07410975 ↗

“Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d” NCT00437307 ↗

“Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.” NCT05882513 ↗

“Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer” NCT05430347 ↗

“Platinum-based chemotherapy (carboplatin: AUC5, d1 or cisplatin 75 mg/m², d1) every 3 weeks (Q3W) for a total of 4 cycles” NCT06868836 ↗

“chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist that the oncologist considers most useful” NCT06922279 ↗

“Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour.” NCT04872634 ↗

“and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.” NCT00669565 ↗

“Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2.” NCT07115095 ↗

“Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles.” NCT03732391 ↗

“Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%.” NCT05835804 ↗

“Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1” NCT06208033 ↗

“Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles” NCT05255471 ↗

“Carboplatin:Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1” NCT06617936 ↗

“All participants will receive three 21-day cycles of carboplatin, paclitaxel, and pembrolizumab as induction therapy.” NCT07428148 ↗

“Patients are going to receive weekly chemotherapy (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]).” NCT03254511 ↗

“Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.” NCT04547504 ↗

“plus carboplatin (at a dose based on an area under the concentration-time curve of 1.5 mg per milliliter per minute)” NCT06831955 ↗

“Participants will receive either BMS-986504 + gemcitabine and carboplatin or BMS-986504 + gemcitabine and cisplatin.” NCT07532902 ↗

“Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.” NCT00423449 ↗

“Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.” NCT04335292 ↗

“IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles” NCT00919984 ↗

“other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.” NCT06190782 ↗

“Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed” NCT00476216 ↗

“Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 6 i.v. injection on day 1” NCT04181372 ↗

“PD-1 inhibitor plus AP regimen chemotherapy (Pemetrexed + Carboplatin or Cisplatin, every 3 weeks) for 4-6 cycles.” NCT07337096 ↗

“patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval” NCT00473954 ↗

“serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.” NCT05957510 ↗

“Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5)” NCT04923906 ↗

“Albumin-bound paclitaxel 260 mg/m², carboplatin AUC = 5, intravenous infusion, Day 1, every 3 weeks for 2 cycles.” NCT07584031 ↗

“Single-agent or combination chemotherapy regimens include dacarbazine, temozolomide, paclitaxel, and carboplatin.” NCT07406724 ↗

“Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles” NCT01927744 ↗

“The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna.” NCT00179816 ↗

“Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT05184712 ↗

“Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.” NCT05080010 ↗

“concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy” NCT03529279 ↗

“Neoadjuvant Chemotherapy with * Toripalimab + Cisplatin + Docetaxel OR * Toripalimab + Carboplatin + Docetaxel” NCT07209189 ↗

“paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)” NCT02789332 ↗

“Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT06396065 ↗

“Carboplatin AUC 5 d1 + Etoposide 100 mg/m² d1-3 + thoracic involved-field radiotherapy (IFRT), q3w × 4 cycles.” NCT07559786 ↗

“Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered” NCT04453930 ↗

“Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);” NCT04055038 ↗

“Paclitaxel (albumin-bound) 130 mg/m2, i.v., d1, 8; Carboplatin AUC 5, i.v. d1; repeat every 21days, 6 cycles.” NCT04661696 ↗

“Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks)” NCT07063329 ↗

“Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.” NCT06719700 ↗

“Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles.” NCT05244798 ↗

“platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute)” NCT05623319 ↗

“albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg were administered intravenously.” NCT07137858 ↗

“Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.” NCT06768307 ↗

“Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.” NCT04201561 ↗

“Platinum-based agent: Cisplatin 75 mg/m² or Carboplatin AUC 5, intravenous infusion on Day 1, every 3 weeks” NCT07381543 ↗

“Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles.” NCT04539977 ↗

“14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5” NCT01669226 ↗

“nab-paclitaxel 100 mg/m2 on days 1, 8, and 15, every 3 weeks plus carboplatin AUC 5 on days 1 every 3 weeks” NCT06175390 ↗

“Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W” NCT04624204 ↗

“Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.” NCT04230408 ↗

“Carboplatin: area under the curve (AUC) = 5, intravenous infusion over more than 30 minutes, Day 2, Q3W;” NCT07015489 ↗

“30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)” NCT06563479 ↗

“chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion” NCT03067610 ↗

“carboplatin and thiotepa, each followed by an infusion of autologous peripheral blood stem cells (PBSCs)” NCT06193759 ↗

“trastuzumab plus pertuzumab plus docetaxel [75 mg/m2, without dose escalation], and carboplatin [AUC 6]” PMID 29223479 ↗ Dec 2017

“Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.” NCT07053215 ↗

“as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1)” NCT05209256 ↗

“Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine” NCT06800339 ↗

“5-Fluorouracil(750 mg/m2/d, CIV d1-5) Cisplatin(75mg/m2,d1)/Carboplatin(AUC5, d1) Toripalimab 240mg d1” NCT04926753 ↗

“Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total” NCT04716751 ↗

“4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )” NCT05179447 ↗

“pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.” NCT03322566 ↗

“Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks” NCT05255302 ↗

“Patients will start with induction chemotherapy of carboplatin, paclitaxel and cetuximab for 6 weeks” NCT06984861 ↗

“Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.” NCT03267654 ↗

“Current best practice recommends Carboplatin combined with Taxol in the treatment of Ovarian cancer.” NCT00466986 ↗

“Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab” NCT06535893 ↗

“Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles.” NCT04907968 ↗

“Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.” NCT05461261 ↗

“Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks.” NCT06371482 ↗

“Carboplatin: administered on Day 1, with an AUC of 5mg/mL/min via IV infusion (maximum dose: 750mg)” NCT07510594 ↗

“Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles.” NCT05675033 ↗

“Chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide per standard of care.” NCT03745222 ↗

“a combination of two drugs administered intravenously: Paclitaxel and Carboplatin (CarboP-pacliT).” NCT02359968 ↗

“carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1” NCT00820755 ↗

“plus Carboplatin (AUC = 5 mg/mL/min, Q3W, IV) or Cisplatin (75 mg/m², Q3W, IV) for up to 4 cycles” NCT07174908 ↗

“inupadenant in combination with chemotherapy SOC carboplatin and paclitaxel in patients with TNBC” NCT03873883 ↗

“One bridging chemotherapy cycle consists of five days of therapy using Carboplatin and etoposide” NCT07291102 ↗

“Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV.” NCT04620954 ↗

“participants receive an intravenous (IV) infusion of paclitaxel 175 mg/m2 plus carboplatin AUC=5” NCT05310331 ↗

“with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W).” NCT04675697 ↗

“1. PLD 30~40mg/m2 D1 + Carboplatin AUC 5 D1 +/- bevacizumab 10mg/kg D1/D15 q4w (for 6-8 cycles)” NCT07340164 ↗

“carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion” NCT01404156 ↗

“Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1” NCT05472467 ↗

“PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen” NCT04860674 ↗

“single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel” NCT05222087 ↗

“Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w” NCT05668767 ↗

“Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum.” NCT01296113 ↗

“Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6” NCT04499118 ↗

“Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1” NCT06914011 ↗

“anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin” NCT03513666 ↗

“neoadjuvant chemotherapy is based on the combination of etoposide and cisplatin/carboplatin.” NCT03523234 ↗

“PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles.” NCT06725368 ↗

“cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle” NCT04124731 ↗

“Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV” NCT04633564 ↗

“* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.” NCT04900623 ↗

“All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)” NCT06703047 ↗

“The three drugs to be used in this research study are thiotepa, etoposide and carboplatin.” NCT02875314 ↗

“CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2” NCT06418789 ↗

“Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin” NCT05775796 ↗

“(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)” NCT05607550 ↗

“then receive Sintilimab + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.” NCT07038460 ↗

“Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin” NCT03475121 ↗

“Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W” NCT05574998 ↗

“All subjects will receive treatment with JSKN033 + cisplatin/carboplatin ± bevacizumab.” NCT07497074 ↗

“Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d” NCT00170625 ↗

“Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;” NCT03823625 ↗

“either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa” NCT03657966 ↗

“Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min)” NCT03989336 ↗

“Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles” NCT06354530 ↗

“Chemotherapy list: * Liposomal Doxorubicin; * Docetaxel; * Paclitaxel; * Carboplatin;” NCT03632798 ↗

“Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)” NCT05424432 ↗

“TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6” NCT02934828 ↗

“systemic intravenous chemotherapy using carboplatin and paclitaxel at standard doses” NCT04811703 ↗

“Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous” NCT02709512 ↗

“cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin” NCT01091168 ↗

“Serplulimab (300mg) + Albumin-bound paclitaxel + Cisplatin/Carboplatin, Q3W, 3cycles” NCT07403435 ↗

“Cisplatin 100 mg/m2 or Carboplatin Area under the curve (AUC) = 5) on days 1, 22, 43” NCT02819752 ↗

“Carboplatin + Paclitaxel administered at each cycle of 21 days (in total 3 cycles).” NCT07637851 ↗

“pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w” NCT03002844 ↗

“Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel” NCT04667793 ↗

“Chemotherapy : paclitaxel and carboplatin, followed by epirubicin-cyclophosphamide” NCT06977542 ↗

“Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection” NCT01588704 ↗

“Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles” NCT06198907 ↗

“B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.” NCT06339060 ↗

“80 mg/m2 paclitaxel every week for 12 weeks (carboplatin-paclitaxel intravenously)” PMID 42372741 ↗ Jul 2026

“Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.” NCT05872724 ↗

“Carboplatin can be used as an alternative if cisplatin toxicity is not tolerated.” NCT06866951 ↗

“Carboplatin injection: 100 mg (10 mL) per vial; AUC 5 intravenously every 3 weeks” NCT07492342 ↗

“Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)” NCT03275506 ↗

“Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5” NCT05157542 ↗

“First-line: Pemetrexed (500 mg/m²) + cisplatin (75 mg/m²) or carboplatin (AUC 5).” NCT07131345 ↗

“Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.” NCT03693248 ↗

“5'azacytidine will be administered on Days 1-7 followed by Carboplatin on Day 15.” NCT03206021 ↗

“plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously)” NCT02095782 ↗

“standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1” NCT06597513 ↗

“Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin)” NCT07092449 ↗

“Albumin Paclitaxel + Carboplatin\*4 Followed by Epirubicin + Cyclophosphamide\*4” NCT07256964 ↗

“High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin” NCT00851110 ↗

“Albumin-bound paclitaxel 125 mg/m² (days 1 \& 8) plus carboplatin AUC 6 (day 1)” NCT07457359 ↗

“Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles” NCT05978193 ↗

“Platinum: Cisplatin 75 mg/m² by IV infusion or Carboplatin AUC=5 mg/mL/min Q3W” NCT06978829 ↗

“DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine” NCT02107950 ↗

“Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin.” NCT03393507 ↗

“chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.” NCT01899066 ↗

“dual-agent chemotherapy (paclitaxel 50 mg/m2, d1 + carboplatin AUC 2, d1, qw)” NCT07016737 ↗

“Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance” NCT01966913 ↗

“Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4” NCT03567642 ↗

“DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel” NCT02107937 ↗

“Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)” NCT02470468 ↗

“Etoposide (100 mg/m2, Days 1-3) + Carboplatin (AUC = 4-5, Day 1) / Cisplatin” NCT06764368 ↗

“Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles” NCT07162506 ↗

“nab-paclitaxel + carboplatin + trastuzumab + pertuzumab (PCbHP, control arm)” NCT07528716 ↗

“Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)” NCT01342237 ↗

“nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d” NCT03917069 ↗

“Carboplatin: intravenous infusion, AUC=2, D1, QW, for 5 consecutive doses.” NCT06888531 ↗

“The choice between Carboplatin or Cisplatin is entrusted to the clinician.” NCT06378892 ↗

“Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks” NCT03899610 ↗

“(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6” NCT00437749 ↗

“The preferred concurrent chemoradiation is carboplatin/paclitaxel weekly.” NCT06906887 ↗

“Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle;” NCT04970043 ↗

“Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle.” NCT06771154 ↗

“camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib” NCT05999149 ↗

“the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD)” NCT01329549 ↗

“followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16” NCT00617942 ↗

“2 cycles of IV P-ICE (pembrolizumab, ifosfamide, carboplatin, etoposide)” NCT04838652 ↗

“Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.” NCT06592326 ↗

“Carboplatin: AUC = 5, day 1 or AUC = 2-3, day 1 and day 8, 21-day cycle” NCT07342283 ↗

“and cisplatin (75 mg/m², intravenous infusion) or carboplatin (AUC = 5)” NCT07244965 ↗

“single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy” PMID 39914419 ↗ Feb 2025

“Etoposide 100mg/m\^2 d1-3+ cisplatin 75mg/m\^2 d1-3 or Carboplatin AUC5” NCT07172412 ↗

“four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).” NCT01066234 ↗

“Cisplatin: 75 mg/m ² or carboplatin：AUC=5 mg/mL/min on Day 1 of 21-day.” NCT07272590 ↗

“From Days 2-3, patients underwent paclitaxel + carboplatin chemotherapy” NCT07068178 ↗

“Cisplatin, pemetrexed, gemcitabine, carboplatin, paclitaxel, docetaxel” NCT06623656 ↗

“regimen includes: 1) Nab-paclitaxel; 2) Carboplatin; 3) Pembrolizumab.” NCT07618793 ↗

“carboplatin, with an area under the curve (AUC) of 4 mg/mL/min (AUC 4)” NCT07591467 ↗

“Radiotherapy followed by Adebrelimab+Bevacizumab+Cisplatin/Carboplatin” NCT07638852 ↗

“Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W” NCT06714708 ↗

“Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks” NCT01487915 ↗

“pemetrexed or gemcitabine in combination with cisplatin or carboplatin” NCT01951586 ↗

“6 cycles of CEV chemotherapy (carboplatin, etoposide, and vincristine)” PMID 39432296 ↗ Nov 2024

“Standard of care therapy, weekly, with either Cisplatin or Carboplatin” NCT06234748 ↗

“squamous: gemcitabine + cisplatin/carboplatin or taxane + carboplatin” NCT04702009 ↗

“carboplatin (AUC 2 mg·min/mL, Days 1, 8, 15, every 4 weeks per cycle)” NCT07371208 ↗

“May include carboplatin with gemcitabine, or paclitaxel or pemetrexed” NCT04966676 ↗

“Albumin paclitaxel 260mg/m2, ivgtt，D1 , Q3W Carboplatin AUC=5, D1，Q3W” NCT07035392 ↗

“Children's Oncology Group - Vincristine/Carboplatin (COG-V/C) regimen” NCT05566795 ↗

“Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total” NCT04326153 ↗

“Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.” NCT04215003 ↗

“Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6” NCT00070629 ↗

“Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)” NCT07101614 ↗

“carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle)” NCT03986528 ↗

“3 cycles carboplatin + paclitaxel maintenance therapy with niraparib” NCT05460000 ↗

“Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.” NCT06056336 ↗

“Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min” NCT05520814 ↗

“R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide.” NCT03450343 ↗

“For non-cisplatin candidates, carboplatin/5fu will be administered.” NCT05307939 ↗

“Carboplatin was calculated using AUC equals 5 for 4 cycles at most.” NCT05407155 ↗

“Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin).” NCT07111520 ↗

“Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin” NCT06732323 ↗

“Platinum drug must be one of cisplatin, carboplatin or nedaplatin;” NCT06424899 ↗

“cisplatin 75 mg/m² or carboplatin AUC 5, plus pemetrexed 500 mg/m²” NCT07084610 ↗

“Weekly carboplatin and paclitaxel at standard doses is preferred.” NCT03234842 ↗

“Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion” NCT03945227 ↗

“carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice” NCT01154140 ↗

“Carboplatin: AUC 4-5, intravenous infusion, every 3 weeks (Q3W).” NCT07033819 ↗

“SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin” NCT05174156 ↗

“pemetrexed/paclitaxel/nab-paclitaxel plus carboplatin/cisplatin” NCT07603661 ↗

“GM102 escalating doses combined with paclitaxel and carboplatin” NCT02978755 ↗

“Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.” NCT06130332 ↗

“carboplatin 200-250mg/m2, IV, Q2w or cisplatin 50mg/m2, IV, Q2w” NCT05898373 ↗

“Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43” NCT00787852 ↗

“Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed” NCT03774732 ↗

“Carboplatin by Area Under Curve (AUC) 2 iv on days 1 \& days 8” NCT03055312 ↗

“Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles” NCT00191646 ↗

“Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy” NCT05742607 ↗

“VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)” NCT01173887 ↗

“Carboplatin: AUC5 (per Calvert formula); maximum dose: 750 mg” NCT07358689 ↗

“carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle” NCT00823719 ↗

“Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks” NCT05245760 ↗

“Either irinotecan or temozolomide or carboplatin or etoposide” NCT05718466 ↗

“Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6” NCT01054482 ↗

“standard-of-care IV carboplatin and IV paclitaxel treatment” NCT03029585 ↗

“cisplatin or carboplatin plus pemetrexed for adenocarcinoma” NCT05583188 ↗

“Pemetrexed/Cisplatin or Carboplatin Pemetrexed maintenance” NCT03353675 ↗

“carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1)” NCT03249142 ↗

“Days 1-57-113-169-225-281-337: Vincristine and Carboplatin;” NCT02265770 ↗

“Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8” NCT04711824 ↗

“Albumin-paclitaxel 175mg/m², carboplatin AUC = 4-5, d1, d22” NCT07457528 ↗

“Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.” NCT06091943 ↗

“Cisplatin, carboplatin, nedaplatin and other platinum drugs” NCT05624099 ↗

“Platinum (carboplatin AUC 5 or cisplatin 75 mg/m²) on day 1” NCT07546383 ↗

“Carboplatin AUC=5, IV, administered on day 1 of each cycle” NCT06627712 ↗

“Carboplatin AUC 5 was given on the first day of each cycle” NCT04950400 ↗

“Platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1)” NCT06969027 ↗

“carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2” NCT06652048 ↗

“Cisplatin, Carboplatin, Docetaxel, Paclitaxel, Pemetrexed” NCT02064491 ↗

“3)Carboplatin(AUC5) + Albumin-bound Paclitaxel(260 mg/m2)” NCT04857164 ↗

“carboplatin injection (AUC=5, administered on Day 1, Q3W)” NCT07554846 ↗

“Chemotherapy treatment with carboplatin and atezolizumab” NCT03147040 ↗